Sling Therapeutics raises $123M Series C to advance oral thyroid eye disease drug

Sling Therapeutics raised $123 million in a Series C financing round to move its oral drug candidate for thyroid eye disease forward.

The capital will fund development of linsitinib, the only late‑stage oral small‑molecule IGF‑1R blocker for the condition, and launch the Phase 3 ORBIT trial, which will test a 150‑mg twice‑daily dose against placebo in 130 patients with results expected in mid‑2028.

Earlier Phase 2b/3 LIDS data showed a 52% proptosis response at 24 weeks and a safety profile consistent with prior studies, positioning the drug to potentially compete with injectable therapies from Amgen and Viridian.